In the complex world of healthcare politics and economics, the choice of drug treatment is not always as straightforward as the product that is most efficacious and has the least number of side effects. In the case of oral cancer therapies, the economic aspects, which centers on who will pay for these new oral agents, are far-reaching. Oral Cancer Therapies: Barriers and Pathways to Reimbursement overviews the current status of reimbursement of cancer therapies within five major European markets, Japan and the US. With a focus on the US market, the issues and changes that are being brought about by the emergence of a new era of oral cancer therapies are discussed, to assess the likelihood that novel, oral cancer therapies will be granted reimbursable status.
